ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Treatment protocols for melanoma

Treatment protocols for melanoma
Literature review current through: Jun 2023.
This topic last updated: May 24, 2023.

INTRODUCTION — The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with melanoma, both for primary treatment of locoregional disease, and for treatment of advanced disease. This is not an exhaustive list; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with melanoma. Additional regimens may be added over time, particularly as treatment for melanoma evolves.

This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with melanoma. Clinicians should refer to the individual disease-oriented topic review that discusses the use of these protocols in appropriate clinical situations.

(See "Systemic treatment of metastatic melanoma lacking a BRAF mutation".)

(See "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations".)

(See "Adjuvant and neoadjuvant therapy for cutaneous melanoma".)

These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.

REGIMENS

Unresectable or metastatic disease

Nivolumab plus ipilimumab followed by nivolumab monotherapy — (table 1)

Nivolumab monotherapy — (table 2)

Pembrolizumab monotherapy — (table 3)

Locoregionally advanced disease

Adjuvant nivolumab monotherapy — (table 4)

Adjuvant pembrolizumab monotherapy — (table 5)

Topic 130661 Version 10.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟